According to a media release issued earlier today by Barvarian Nordic, the company expects to complete enrollment of patients in the randomized, double-blind, placebo-controlled, multi-center, Phase III PROSPECT trial of Prostvac VF within the next 12 months. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, chemotherapy-naïve, immunotherapy, metastatic, PROSTVAC-VF | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site